<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368665</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_CCA_301B</org_study_id>
    <nct_id>NCT02368665</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination
      therapy on patients of essential hypertension who are not properly controlled by amlodipine
      besylate monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in siDBP at week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ΔsiDBP ≥ 10 mmHg and ΔsiSBP ≥ 20 mmHg after 8 weeks</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving siDBP ＜ 90 mmHg and siSBP ＜ 140 mmHg after 8 weeks</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>AML 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML 5mg / CC 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML 10mg / CC 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>- Daily oral administration for 8 weeks</description>
    <arm_group_label>AML 5mg</arm_group_label>
    <other_name>Novarsc 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg, Candesartan cilexetil 16mg</intervention_name>
    <description>- Daily oral administration Amlodipine 5mg for 8 weeks</description>
    <arm_group_label>AML 5mg / CC 16mg</arm_group_label>
    <other_name>Novarsc 5mg, Atacand 16mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg, Candesartan cilexetil 16mg</intervention_name>
    <description>- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks</description>
    <arm_group_label>AML 10mg / CC 16mg</arm_group_label>
    <other_name>Novarsc 10mg, Atacand 16mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥ 19 and ≤ 75 years old

          -  Subject with essential hypertension

          -  Subject who have voluntarily agreed to participate in the trial and signed the written
             informed consent form, after having listened to the purpose, method, and effect of the
             clinical trial

        Exclusion Criteria:

          -  Subject who is siDBP ≥ 120 mmHg or siSBP ≥ 200 mmHg at Visit 1 (screening)

          -  Subject with difference in the mean blood pressure of over 10 mmHg for siDBP or 20
             mmHg for siSBP between both arms at the screening visit

          -  Subject with known or suspected secondary hypertension [Including but not limited to
             any of the following: renovascular diseases, adrenal medullary and cortical
             hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or
             bilateral renal artery stenosis, Cushing's syndrome, pheochromo-cytoma, polycystic
             kidney disease, etc.]

          -  Subject with symptomatic orthostatic hypotension(a sudden fall in siDBP of at least 10
             mmHg or siSBP of at least 20 mmHg after standing compared with blood pressure from the
             sitting or supin position)

          -  Subject with type 1 or type 2 diabetes mellitus with poor glucose control (defined as
             subject on inculin treatment, with HbA1c &gt; 9.0% or with a modification in the oral
             anti-hyperglycemic medication regiment within the past 12 weeks prior to visit 1)

          -  Subject with severe heart disease(congestive heart failure(NYHA class 3 or 4),
             ischemic heart disease within the past 6 months(unstable angina, myocardial
             infarction), peripheral blood vascula disease, history of Percutaneous Transluminal
             Coronary Angioplasty or coronary artery bypass grafting)

          -  Subject with clinically significant ventricular tachycardia, atrial fibrillation,
             atrial flutter or other clinically significant arrhythmia

          -  Subject with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, haemodynamically relevant stenosis of the aortic or
             mitral valve

          -  Subject with cardiogenic shock

          -  Subject with severe cerebrovascular disease (history of stroke, cerebral infraction,
             or cerebral hemorrhage within the past 6 months)

          -  Subject with a history of or ongoing wasting disease, autoimmune diseases(rheumatoid
             arthritis, systemic lupus erythematosus, etc.) or connective tissue disease

          -  Subject with known moderate or malignant retinopathy (history of retinal signs of
             hemorrhage, visual impairment, retinal microaneurysm etc. within the past 6 months)

          -  Subject with any surgical or medical condition of the gastrointestinal tract that
             might sugnificantly alter the absorption, distribution, metabolism or excretion of the
             drug

          -  Subject with a history of malignant tumors including leukemia and lymphoma within the
             past 5 yesrs(except for localized basal cell carcinoma of the skin)

          -  Subject with any chronic inflammatory condition needing chronic anti-inflammatory
             therapy

          -  Subject with chronic kidney disase on dialysis

          -  Subject with the following clinically significant laboratory abnormalities:

               -  AST or ALT &gt; 3 x Upper Limit Normal(ULN)

               -  Serum Creatinine &gt; 1.5 ULN

               -  Serum potassium &lt; 3.5 mmol/L or &gt; 5.5mmol/L

          -  Subject requiring concomitant use of other antihypertensive or contraindicated drugs
             during the entire study period

          -  Subject with known or suspected contraindications, including history of allergy or
             hypersensitivity to ARB or dihydropyridine derivatives

          -  Subject who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or ARB

          -  Pregnant women or lactating mother, women suspected of being pregnant, women who wish
             to be pregnant during the study or women of child-bearing potential who are not using
             medically acceptable methods of contraception (oral contraceptinve, intra-uterine
             device, condom, etc.), except for women with surgical sterilization. Pre-menopausal
             women who are not surgically sterilized must have a negative pregnancy test result at
             Visit1 and maintain acceptable methods of contraception throughout the study. preiodic
             abstinence (eg. symptothermal, calendar, post-ovulation methods), or hormonal
             contraceptive are not acceptable methods of contraception

          -  History of drug or alcohol abuse within the past 1 year

          -  Use of other investigational products within the past 4 weeks

          -  Subject who are jdged unsuitable to participate in the study in the opinion of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seungjea Tahk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geunsuk Song</last_name>
    <phone>+82-2-6740-2440</phone>
    <email>kssong1212@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eunji Kim</last_name>
    <phone>+82-2-6740-2443</phone>
    <email>keunji@cj.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Sungsim Hospital</name>
      <address>
        <city>Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Baik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Baik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Baik Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital Catholic University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seungjae Tahk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

